Richard Cutler

Richard Cutler, Ph.D.

Vice President, Clinical Science

Dr. Richard Cutler, Ph.D., joined Kronos Bio in June 2022, and serves as Vice President, Clinical Science. In this role his primary responsibility is for the development and execution of clinical trial protocols, analysis and preparation of data, engagement of key opinion leaders and preparation of regulatory documents.

Richard joined Kronos Bio from Nektar Therapeutics, where he was the head of Clinical Science. He is a trained cell biologist and worked on preclinical target and compound characterization prior to moving into clinical development. Before Nektar, Richard held positions at several biotech companies focusing on targeted therapies, including SUGEN, Exelixis, Onyx Pharmaceuticals and Puma Biotechnology.

Richard received a B.S. in Biology from Loyola University of Chicago.  He received a Ph.D. in Cell and Molecular Biology from Northwestern University, in the laboratory of Dr. Mary Hunzicker-Dunn, studying the role of hormonal regulation of signal transduction proteins in the ovary. He also completed a post-doctoral fellowship at the National Cancer Institute in the laboratory of Dr. Deborah Morrison, studying structure/function analysis of the oncogene Raf. Richard has been a guest speaker in over 75 classrooms, ranging from elementary to medical school, on his role as a cancer scientist.  Richard serves on the Academic Advisory Board and is the Director of the Board for the University of San Francisco’s Professional Science Master’s (PSM) in Biotechnology program and for the past eight years has been a guest lecturer at Keck School of Medicine of USC on precision medicine in clinical trials.

As our Vice President of Clinical Science, Richard utilizes his clinical and pre-clinical expertise to ensure that Kronos Bio’s clinical trials test our hypothesis of targeting transcription factor networks, are scientifically rigorous, and put us in a position to deliver on the company’s mission to bring life-changing therapies to market.